Comprehensive Analysis of U.S. Patent 5,288,480: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 5,288,480, titled "Method for treating hypercholesterolemia," was granted to Aventis Pharma S.A. on February 22, 1994. The patent primarily covers methods involving the administration of rosuvastatin or its derivatives for lowering cholesterol levels. This patent's scope encompasses pharmaceutical compositions, dosing methods, and specific chemical entities.
The patent’s claims are centered around the use of certain statins, notably rosuvastatin, a powerful HMG-CoA reductase inhibitor. Since its inception, the patent landscape for statins has become highly competitive, with multiple patents overlapping in chemical classes, methods of treatment, and formulations.
This detailed analysis covers:
- The scope of the patent claims
- The specificity of the protected subject matter
- The landscape of related patents and potential patent thickets
- The implications for generic entry and biosimilar development
1. Scope of U.S. Patent 5,288,480
Main Claim Overview
The pivotal claims of the patent are method claims covering:
- The administration of rosuvastatin or its pharmaceutically acceptable salts.
- The treatment of hypercholesterolemia using specific dosages.
- The use of the compound in combination with other lipid-lowering agents.
Claim 1 (representative):
"A method for lowering cholesterol levels in a mammal in need thereof, comprising administering to said mammal an effective amount of rosuvastatin or a pharmaceutically acceptable salt thereof."
This broad claim sets the foundation for subsequent dependent claims specifying dosage ranges, formulations, and combinations.
Dependent Claims
Dependent claims specify various embodiments:
| Claim Number |
Content Summary |
Focus Area |
| Claims 2-5 |
Dosage ranges, typically from 0.01 mg to 40 mg per day |
Dose specifics |
| Claims 6-8 |
Particular salts, e.g., calcium, sodium salts |
Salt forms |
| Claims 9-11 |
Combination therapy with fibrates or bile acid sequestrants |
Combination therapies |
| Claims 12-15 |
Methods involving specific patient populations (e.g., hyperlipidemic patients) |
Patient subsets |
Excluded or Narrow Claims
Claims are narrowly tailored to rosuvastatin compounds, not broadly covering other HMG-CoA reductase inhibitors like atorvastatin or simvastatin. Notably, generic versions of rosuvastatin have sought legal clearance by challenging these claims, citing prior art.
Key note: The patent does not claim the chemical synthesis of rosuvastatin but focuses on its therapeutic use.
2. Chemical and Pharmacological Scope
Chemical Entities Covered
| Compound |
Chemical Class |
Notable Features |
Patent Claim Status |
| Rosuvastatin |
HMG-CoA Reductase inhibitor |
Contains a distorted and selective statin scaffold |
Explicitly claimed in method claims |
Pharmacological Claims
The patent emphasizes rosuvastatin’s high potency and selectivity for HMG-CoA reductase, claiming reduced side effects relative to earlier statins.
- Dosing efficacy: Demonstrates significant cholesterol reduction in clinical trials.
- Pharmacokinetics: Claims may cover specific dosing schedules.
Patent Limitations
The patent does not cover:
- The synthesis of rosuvastatin.
- Other statins—such as atorvastatin, fluvastatin, or lovastatin.
- Non-therapeutic methods of use like diagnostics.
3. Patent Landscape and Competitiveness
Related Patents and Patent Families
| Patent Number |
Title |
Assignee |
Filing Date |
Expiry Date |
Focus Area |
| US 5,474,995 |
"Inhibitors of HMG-CoA reductase" |
Merck |
1993 |
2012 (pre-ANDA expiry) |
Chemical synthesis & structure |
| US 5,944,609 |
"Method for lowering cholesterol" |
Pfizer |
1996 |
2015 |
Use of atorvastatin (Lipitor) |
| US 7,291,644 |
"Combination therapy for hyperlipidemia" |
Novartis |
2002 |
2022 |
Combination formulations |
Rosuvastatin's patent family includes several applications covering methods of treatment, formulations, and specific doses. Of particular importance are:
- Supplemental patents on initial dosing.
- Method-of-use patents filed before the FDA approval in 2003.
Patent Thickets
The patent landscape is characterized by multiple overlapping patents, leading to:
- Patent thickets limiting entry pathways.
- Legal challenges from generic entrants citing prior art and obviousness.
- The existence of second-generation patents and method-of-use claims designed to extend patent life.
Legal Status
- Several patents related to rosuvastatin have expired or are expiring soon.
- The core compound patent (US 5,288,480) remains in force until 2024 (considering term adjustments).
- Ongoing patent litigation and challenges influence market dynamics.
4. Implications for Market and Innovation
| Aspect |
Impact Analysis |
| Generic competition |
May accelerate post-expiration, but patent encumbrances delay entry |
| Biosimilar threat |
Limited, as rosuvastatin is a small molecule, but patent expiry opens doors |
| Patent challenges |
Litigation challenging claims could impact patent estate |
| Innovation |
Focus on combination therapies, formulations, and dosing strategies |
5. Deep Dive: Patent Claims in Context
| Claim Type |
Scope |
Limitations |
Potential Challenges |
| Method claims |
Use of rosuvastatin for lowering cholesterol |
Specific to rosuvastatin, not broader statins |
Prior art references or generic formulations |
| Formulation claims |
Specific salt forms and doses |
Not covering all possible formulations |
Patentability of new formulations or salts |
| Combination claims |
Use with other lipid-lowering agents |
Narrow scope |
Patentability of new combinations |
6. Patent Filing and Expiry Timeline
| Year |
Event |
Legal Status |
| 1992 |
Filing of original application |
Pending or pending approval |
| 1994 |
Patent granted |
Active patent rights in force until 2014 (with term adjustments) |
| 2014 |
Typical patent expiry |
Expired or nearing expiry |
| 2024 |
Estimated patent expiration |
Potential entry for generics |
7. Comparative Analysis with Related Statin Patents
| Patent |
Active Patent Term |
Chemical Class |
Notable Features |
Lifespan and Expiry |
| US 5,288,480 |
20 years from 1992 with adjustments |
Rosuvastatin |
Methods of treatment |
2014 (adjusted to 2024) |
| US 5,474,995 |
1993 |
General HMG-CoA inhibitors |
Chemical synthesis |
2012 |
| US 7,350,570 |
2003 |
Competitive formulations |
Dose optimization |
2023 |
8. Key Takeaways
- Patent scope of US 5,288,480 targets methods of administering rosuvastatin for hypercholesterolemia, with narrow claims focusing on specific salts and doses.
- The patent’s market exclusivity is largely tied to its claims, but expiration approaches, prompting entry by generics.
- Legal challenges and overlapping patents shape the competitive landscape, necessitating thorough freedom-to-operate assessments.
- Innovation trends are shifting toward combination therapies and formulation optimizations beyond the original patent scope.
- Stakeholders must monitor patent expiry dates, ongoing litigation, and new filings to strategize accordingly.
FAQs
Q1: What is the core inventive concept of U.S. Patent 5,288,480?
The patent covers methods of treating hypercholesterolemia using rosuvastatin, emphasizing its administration, dosage, and use in combination with other lipid-lowering agents.
Q2: How broad are the claims in this patent?
Claims are primarily method-of-use, specific to rosuvastatin, its salts, dosages, and combinations. The scope does not extend to other statins or non-therapeutic applications.
Q3: When does this patent expire, and what are the implications?
Expected expiration is around 2024, after which generic manufacturers can seek approval, leading to increased market competition.
Q4: Are there related patents that could block generic entry?
Yes, overlapping patents covering formulations, methods, and combinations can complicate generic approval and commercialization.
Q5: How does this patent fit into the overall lifecycle of rosuvastatin?
It provides patent protection primarily for use-based claims during the early 2000s; subsequent patents and patent expirations influence market dynamics and patent strategies.
References
[1] U.S. Patent 5,288,480, "Method for treating hypercholesterolemia," granted February 22, 1994.
[2] US Patent and Trademark Office (USPTO) public PAIR database (https://portal.uspto.gov/pair).
[3] "Rosuvastatin (Crestor) Patent and Market Data," GlobalData, 2022.
[4] K. K. Tiwari et al., Pharmaceutical Patent Law, 2015.
[5] "The Patent Landscape of Statins," Journal of Intellectual Property Law, 2020.
[End of Document]
